PCAC July 23-24 Public Comment Window Set: Written Submissions Close July 9, Oral Presentation Requests Close June 30
The Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 — at which seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) will be discussed for 503A compounding inclusion — now has firm public-comment deadlines. Written submissions are due July 9, 2026 via regulations.gov; oral presentation requests close June 30, with the FDA allocating presentation slots after review. The PCAC review follows the April 23, 2026 effective date when 12 peptides came off the FDA's Category 2 bulks list. Industry stakeholders, patient groups, and clinicians are organizing through the SSRPi network and the Alliance for Pharmacy Compounding to coordinate testimony. The combined regulatory cycle — PCAC plus the parallel April 30 503B bulks-list proposal closing June 29 — will reshape the compounding-pharmacy economy through 2027 and determine which research peptides remain accessible through licensed channels.